Statins are entrenched in the dyslipidemia treatment algorithm for both primary and secondary prevention, but despite their use, a substantial percentage of patients have residual cardiovascular risk, driving the need for new add-on therapies that can be used alongside statin treatment for further risk reduction. Brazilians can access a wide range of dyslipidemia drugs through federally funded, and state-and municipal-administered programs. Yet, several drugs, including the most potent statins and cholesterol absorption inhibitors, are absent from the government’s reimbursable drugs list, the Relação Nacional de Medicamentos Essenciais (RENAME), leaving many patients to pay for them out-of-pocket. Through the 2013-2018 period, the Brazilian dyslipidemia market is poised for additional entries—statin adjuncts and/or niche therapies—that will contribute to substantial sales growth.
Questions Answered in This Report:
- The Brazilian dyslipidemia market will grow 4.3% annually from 2013 to 2018 with increases in the rates of dyslipidemia diagnosis and drug treatment and with the launch and uptake of more potent statins and novel therapies. What was the size of the Brazilian dyslipidemia market in 2013? How large will the market be in 2018? How will novel therapies emerging for dyslipidemia in the next five years change the Brazilian market? What factors will drive growth in this market? What are the opportunities for dyslipidemia drug manufacturers and developers?
- While surveyed Brazilian physicians place relatively little emphasis on whether a drug is available generically when selecting a dyslipidemia drug therapy, generics and “similares” (similar products to the reference drug) accounted for 70% of dyslipidemia sales in Brazil in 2013. What factors are paramount to drug selection in Brazil? How will generic erosion affect MNC brands and physician prescribing patterns in Brazil? What will be the impact of new Brazilian government rules that require a minimum 35% reduction from the price of reference drugs for their “similares,” and how will permitted “similares” substitution impact the split between MNC brand and non-originator usage in 2018? Which brand will be the best-selling product in 2018?
- Brazil has a high rate of full or partial government payment for many dyslipidemia therapies, yet patients are expected to shoulder more of the cost of certain agents. Which agents enjoy government coverage, and which do patients largely access through private insurance or out-of-pocket expenditure? For which therapies might cost limit uptake given government coverage rates and patients’ income levels? How to brand prices in Brazil compare with those of the brands in other countries?
Markets covered: Brazil.
Primary research: 8 country-specific interviews with cardiologists, endocrinologists, and general practitioners (GPs).
Epidemiology: Total prevalent cases of dyslipidemia, 2013-2023; total diagnosed and drug-treated prevalent cases of dyslipidemia in Brazil, 2013 and 2018.
Population segments in market forecast: Low-to-moderate risk patients (primary prevention); coronary heart disease (CHD) and CHD risk-equivalent patients (secondary prevention).
Emerging therapies: Phase III: 11 drugs.
Courtney Walls, M.P.H.